RESEARCH PAPER
Sexual maturity staging and affecting immune-hormonal factors in children aged 6-18 years living with HIV: experience from tertiary care center in North India
1
Atal Bihari Vajapayee Institute of Medical Sciences and Ram Manohar Lohia Hospital, New Delhi, India
Submission date: 2022-04-07
Final revision date: 2023-02-24
Acceptance date: 2023-03-10
Publication date: 2024-11-30
Corresponding author
HIV & AIDS Review 2024;23(4):323-329
KEYWORDS
TOPICS
ABSTRACT
Background:
Children living with human immunodeficiency virus (HIV) may experience growth failure and delay in sexual maturation. The aim of the study was to investigate sexual maturity rating and hormonal levels in children living with HIV aged 6-18 years.
Material and methods:
In this cross-sectional observational study over 18 months, 69 subsequent children living with HIV (CLHIV), aged between 6- and 18-years, attending antiretroviral therapy (ART) clinic were enrolled. Clearance from the Institutional Ethical Committee and informed consents were obtained.
Results:
Baseline data of 69 children showed male predominance (66.7%), vertical transmission (95.7%), normal body mass index (BMI) (71%), immunocompetency (3/4th), and low viral load (2/3rd). Sexual maturity staging revealed that the majority were pre-pubertal (pubic hair (PH) stage 1: boys = 54.3%, girls = 39.1%; testicular volume stage 1 = half; breast stage 1 = 39.1%). Delayed puberty was observed in 6.5% of boys and 8.6% of girls. The mean age of menarche was 13 ± 1.4 years. Hormonal levels between boys and girls showed statistically significant difference in levels of follicular stimulating hormone (FSH), luteinizing hormone (LH), prolactin, estrogen, and Free androgen index (FAI). Luteinizing hormone had high sensitivity and specificity (cut-off value = 1.06, sensitivity = 95.5%, specificity = 83.3%) for predicting stage 2 of testicular volume (gonadarche), and in girls (cut-off value = 1.74, sensitivity = 92.9%, specificity = 88.9%). For FSH in girls, cutoff value of 5.42 provided high sensitivity (92.9%) in predicting thelarche (breast stage 2). No statistically significant association was observed with CD4 categories (p = 0.3), viral load categories (p = 0.2), age at ART initiation, and BMI categories with pubertal stages. Among antiretroviral drugs, less than 50% of children on abacavir, zidovudine, and lopinavir/ritonavir had attained pubertal onset (in girls, breast stage ≥ 2; in boys, testicular volume (TV) stage ≥ 2).
Conclusions:
Delayed puberty was observed in 6.5% of boys and 8.6% of girls. Median ages at thelarche and gonadarche were higher in included children when compared to healthy school going children. HIV infection may have a negative effect on the sexual maturity rating in CLHIV.
Children living with human immunodeficiency virus (HIV) may experience growth failure and delay in sexual maturation. The aim of the study was to investigate sexual maturity rating and hormonal levels in children living with HIV aged 6-18 years.
Material and methods:
In this cross-sectional observational study over 18 months, 69 subsequent children living with HIV (CLHIV), aged between 6- and 18-years, attending antiretroviral therapy (ART) clinic were enrolled. Clearance from the Institutional Ethical Committee and informed consents were obtained.
Results:
Baseline data of 69 children showed male predominance (66.7%), vertical transmission (95.7%), normal body mass index (BMI) (71%), immunocompetency (3/4th), and low viral load (2/3rd). Sexual maturity staging revealed that the majority were pre-pubertal (pubic hair (PH) stage 1: boys = 54.3%, girls = 39.1%; testicular volume stage 1 = half; breast stage 1 = 39.1%). Delayed puberty was observed in 6.5% of boys and 8.6% of girls. The mean age of menarche was 13 ± 1.4 years. Hormonal levels between boys and girls showed statistically significant difference in levels of follicular stimulating hormone (FSH), luteinizing hormone (LH), prolactin, estrogen, and Free androgen index (FAI). Luteinizing hormone had high sensitivity and specificity (cut-off value = 1.06, sensitivity = 95.5%, specificity = 83.3%) for predicting stage 2 of testicular volume (gonadarche), and in girls (cut-off value = 1.74, sensitivity = 92.9%, specificity = 88.9%). For FSH in girls, cutoff value of 5.42 provided high sensitivity (92.9%) in predicting thelarche (breast stage 2). No statistically significant association was observed with CD4 categories (p = 0.3), viral load categories (p = 0.2), age at ART initiation, and BMI categories with pubertal stages. Among antiretroviral drugs, less than 50% of children on abacavir, zidovudine, and lopinavir/ritonavir had attained pubertal onset (in girls, breast stage ≥ 2; in boys, testicular volume (TV) stage ≥ 2).
Conclusions:
Delayed puberty was observed in 6.5% of boys and 8.6% of girls. Median ages at thelarche and gonadarche were higher in included children when compared to healthy school going children. HIV infection may have a negative effect on the sexual maturity rating in CLHIV.
REFERENCES (27)
1.
Global HIV and AIDS statistics. Fact sheet 2021. Available at: https://www.unaids.org/en/reso....
2.
UNICEF. HIV and AIDS in Adolescents. UNICEF data 2021. Available at: https://data.unicef.org/topic/....
3.
National AIDS Control Organization. HIV Facts and Figures. MoHFW 2021. Available at: http://naco.gov.in/hiv-facts-f....
4.
Cruz MLS, Cardoso CA. Perinatally infected adolescents living with human immunodeficiency virus (perinatally human immunodeficiency virus). World J Virol 2015; 4: 277-284.
5.
Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, et al. Pubertal development in HIV-infected African children on first-line antiretroviral therapy. AIDS Lond Engl 2015; 29: 609-618.
6.
Pozo J, Argente J. Delayed puberty in chronic illness. Best Pract Res Clin Endocrinol Metab 2002; 16: 73-90.
7.
Zaid D, Greenman Y. Human immunodeficiency virus infection and the endocrine system. Endocrinol Metab 2019; 34: 95-105.
8.
Gertner JM, Kaufman FR, Donfield SM, Sleeper LA, Shapiro AD, Howard C, et al. Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr 1994; 124: 896-902.
9.
Chantry CJ, Frederick MM, Meyer WA, Handelsman E, Rich K, Paul ME, et al. Endocrine abnormalities and impaired growth in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2007; 26: 53-60.
10.
de Martino M, Tovo PA, Galli L, Gabiano C, Chiarelli F, Zappa M, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS Lond Engl 2001; 15: 1527-1534.
11.
Williams PL, Abzug MJ, Jacobson DL, Wang J, Van Dyke RB, Hazra R, et al. Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. AIDS 2013; 27: 1959-1970.
12.
Buchacz K, Rogol AD, Lindsey JC, Wilson CM, Hughes MD, Seage GRI, et al. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. JAIDS J Acquir Immune Defic Syndr 2003; 33: 56-65.
13.
Mbwile G. Growth and pubertal development among HIV infected children aged 8-18 years in Dar es salaam. Muhimbili University of Health and Allied Sciences 2012.
14.
Rolland-Guillard L. Delayed puberty in perinatally HIV-infected adolescents in Thailand. Université de Strasbourg 2016.
15.
Interim who clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance. Available at: https://www.who.int/hiv/pub/gu... staging.pdf.
16.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44: 291-303.
17.
Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45: 13-23.
18.
Emmanuel M, Bokor BR. Tanner Stages. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing 2021. Available at: http://www.ncbi.nlm.nih.gov/bo....
19.
Bellavia A, Williams PL, DiMeglio LA, Hazra R, Abzug MJ, Patel K, et al. Delay in sexual maturation in perinatally HIV-infected youth is mediated by poor growth. AIDS (London, England) 2017; 31: 1333.
20.
Surana V, Dabas A, Khadgawat R, Marwaha R, Sreenivas V, Ganie M, et al. Pubertal onset in apparently healthy Indian boys and impact of obesity. Indian J Endocrinol Metab 2017; 21: 434.
21.
Khadgawat R, Marwaha RK, Mehan N, Surana V, Dabas A, Sreenivas V, et al. Age of onset of puberty in apparently healthy school girls from Northern India. Indian Pediatr 2016; 53: 383-387.
22.
Sun Y, Tao F, Su PY; China Puberty Research Collaboration. National estimates of pubertal milestones among urban and rural Chinese boys. Ann Hum Biol 2012; 39: 461-467.
23.
Juul A, Teilmann G, Scheike T, Hertel NT, Holm K, Laursen EM, et al. Pubertal development in Danish children: comparison of recent European and US data. Int J Androl 2006; 29: 247-255; discussion 286-290.
24.
Iloh ON, Iloh KK, Ubesie AC, Emodi IJ, Ikefuna AN, Ibeziako NS. Comparison of Tanner staging of HIV-infected and uninfected girls at the University of Nigeria Teaching Hospital, Ituku/Ozalla, Enugu, Nigeria. J Pediatr Endocrinol Metab 2017; 30: 725-729.
25.
Bakeera-Kitaka S, McKellar M, Snider C, Kekitiinwa A, Piloya T, Musoke P, et al. Antiretroviral therapy for HIV-1 infected adolescents in Uganda: Assessing the impact on growth and sexual maturation. J Pediatr Infect Dis 2008; 3: 97-104.
26.
Chiarelli F, Verrotti A, Galli L, Basciani F, de Martino M. Endocrine dysfunction in children with HIV-1 infection. J Pediatr Endocrinol Metab 1999; 12: 17-26.
27.
de Martino M, Galli L, Chiarelli F, Verrotti A, Rossi ME, Bindi G, et al. Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 serum levels in children with perinatal HIV-1 infection. Clin Immunol Orlando Fla 2000; 94: 212-218.
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
